IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1425
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$8.4B
Yat-Gai Au
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$RGC Regencell Bioscience Holdings Ltd | 54 | 20 | 54 | 95 | - | - | -295.0% | -249.1% | - | - | - | - | 0.0% | 0.0x | $8.4B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Regencell Bioscience Holdings Ltd (RGC) receives a "Hold" rating with a composite score of 53.8/100. It ranks #1425 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for RGC.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 20 | 3 | +17ALPHA |
| MOMENTUM | 95 | 98 | -3NEUTRAL |
| VALUATION | 54 | 44 | +10ALPHA |
| INVESTMENT | 53 | 94 | -41DRAG |
| STABILITY | 30 | 16 | +14ALPHA |
| SHORT INT | 82 | 91 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -295.0% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Regencell Bioscience Holdings Ltd (RGC) as a Hold with a composite score of 53.8/100 at a current price of $26.29. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Regencell Bioscience Holdings Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 53.8/100 places it at rank #1425 in our full universe.
No Moat
Medium
Poor
Fair Value
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Regencell Bioscience Holdings Ltd represents a hold based on multi-factor quantitative performance.
Our model assigns Regencell Bioscience Holdings Ltd a Hold rating, with a composite score of 53.8/100 and 3 out of 5 stars. Ranked #1425 of 7,333 stocks, RGC presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
Regencell Bioscience Holdings Ltd registers a weak quality score of just 20/100, indicating significant profitability challenges. The company reports a return on equity of -295.0% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
RGC's value score of 54/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/B ratio of 2967.78x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
With an investment score of 53/100, RGC exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -249.1% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
Regencell Bioscience Holdings Ltd (RGC) is exhibiting exceptional momentum with a score of 95/100, placing it among the strongest trending stocks in the market. Revenue growth data is not currently available, while a beta of 1.00 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting RGC may continue to benefit from strong institutional interest and positive price trends.
RGC's stability score of 30/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.00 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
RGC's short interest factor score of 82/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. As a mid-cap company with a market capitalization of $8.4B, Regencell Bioscience Holdings Ltd benefits from the generally lower volatility and deeper liquidity associated with its size class.
Regencell Bioscience Holdings Ltd is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1425 of 7,333 overall (81st percentile). Key comparisons include ROE of -295.0% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While RGC currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (95) vs Quality (20) — closing this gap could shift the rating.
ROE 15425% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 100% BELOW SECTOR MEDIAN (FAVORABLE)
Div. Yield NaN% BELOW SECTOR MEDIAN
U.S. stock indexes closed mixed on Wednesday, with the Dow Jones Industrial Average gaining 0.16%. In contrast, the S&P 500 fell by 0.34%, and the Nasdaq Composite experienced a larger decline of 0.94%. Regencell Bioscience led the market, while AST SpaceMobile lagged.
S&P 500 futures are rising in premarket trading. Regencell Bioscience Holdings Ltd. (RGC) and Weatherford International PLC (WFRD) are leading the gains, up 16.4% and 9.7% respectively, as U.S. stock markets prepare to open.
S&P 500 futures were flat in premarket trading. Regencell Bioscience Holdings Ltd. (RGC) saw a 5.4% increase, and AngloGold Ashanti PLC (AU) was up 3.7% in early trading.
U.S. stock indexes experienced a downturn on Friday, with the Dow Jones, S&P 500, and Nasdaq Composite all closing in negative territory. Regencell Bioscience (RGC) was noted as taking the biggest hit among listed stocks. Other mentioned tickers include RKLB, ASTS, CPNG, and PSTG.
Regencell Bioscience Holdings Limited (RGC) has emerged as the top-performing pharmaceutical stock year-to-date. While the broader S&P healthcare index (XLV) showed moderate gains, RGC has significantly outpaced the sector. This performance highlights individual company success within the healthcare industry during 2025.
Above 50MA
37.18%
Net New Highs
+51081